Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-701-7901
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.97 million
Profitability
Miscellaneous
Employees146
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable
Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions
What is Kindred Biosciences' stock symbol?
Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."
How were Kindred Biosciences' earnings last quarter?
Kindred Biosciences Inc (NASDAQ:KIN) issued its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.37) by $0.02. The biopharmaceutical company had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.55 million. Kindred Biosciences had a negative return on equity of 58.86% and a negative net margin of 1,461.28%. View Kindred Biosciences' Earnings History.
When is Kindred Biosciences' next earnings date?
What price target have analysts set for KIN?
8 equities research analysts have issued 12 month target prices for Kindred Biosciences' stock. Their forecasts range from $8.50 to $25.00. On average, they expect Kindred Biosciences' stock price to reach $14.44 in the next year. This suggests a possible upside of 95.9% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.
What is the consensus analysts' recommendation for Kindred Biosciences?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.
Has Kindred Biosciences been receiving favorable news coverage?
Media coverage about KIN stock has trended very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Kindred Biosciences earned a news impact score of -3.9 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Kindred Biosciences.
Are investors shorting Kindred Biosciences?
Kindred Biosciences saw a decline in short interest in October. As of October 31st, there was short interest totalling 815,100 shares, a decline of 8.3% from the September 30th total of 889,100 shares. Based on an average trading volume of 113,500 shares, the short-interest ratio is currently 7.2 days. Approximately 2.2% of the company's shares are sold short. View Kindred Biosciences' Current Options Chain.
Who are some of Kindred Biosciences' key competitors?
Some companies that are related to Kindred Biosciences include BELLUS Health (BLUSF), Supernus Pharmaceuticals (SUPN), Y-mAbs Therapeutics (YMAB), Radius Health (RDUS), Esperion Therapeutics (ESPR), Odonate Therapeutics (ODT), Arvinas (ARVN), Endo International (ENDP), Theravance Biopharma (TBPH), ZEALAND PHARMA/S (ZEAL), Opko Health (OPK), Principia Biopharma (PRNB), Wave Life Sciences (WVE), Karyopharm Therapeutics (KPTI) and Rhythm Pharmaceuticals (RYTM).
What other stocks do shareholders of Kindred Biosciences own?
Who are Kindred Biosciences' key executives?
Kindred Biosciences' management team includes the folowing people:
- Dr. Richard Chin, Co-Founder, CEO & Director (Age 52)
- Ms. Denise M. Bevers, Co-Founder, Pres, COO, Sec. & Director (Age 52)
- Ms. Wendy K. Wee, Chief Financial Officer (Age 66)
- Dr. Hangjun Zhan, Chief Scientific Officer (Age 59)
- Ms. Katja Buhrer, VP of Corp. Devel. & Investor Relations
Who are Kindred Biosciences' major shareholders?
Kindred Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Dalton Greiner Hartman Maher & Co. (0.36%), Teton Advisors Inc. (0.09%), Gabelli Funds LLC (0.04%) and Tower Research Capital LLC TRC (0.02%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.
Which major investors are buying Kindred Biosciences stock?
How do I buy shares of Kindred Biosciences?
Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Kindred Biosciences' stock price today?
One share of KIN stock can currently be purchased for approximately $7.37.
How big of a company is Kindred Biosciences?
Kindred Biosciences has a market capitalization of $288.09 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.View Additional Information About Kindred Biosciences.
What is Kindred Biosciences' official website?
How can I contact Kindred Biosciences?
Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]
MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
